Drug intelligence / Profile preview

clarithromycin + vinorelbine

Development stage: Discontinued
Lead developer: Savara
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A drug combination where clarithromycin, a macrolide antibiotic, significantly inhibits the metabolism of vinorelbine, a semi-synthetic vinca alkaloid used in cancer treatment. This interaction occurs through clarithromycin's inhibition of CYP3A and P-glycoprotein, which can lead to increased vinorelbine blood levels and potentially severe neutropenia. Clinical evidence shows patients receiving both drugs concurrently had significantly higher incidence of grade 4 neutropenia (31.6%) compared to those receiving vinorelbine alone (2.5%).

Targets

TUBB (Tubulin (alpha and beta subunits))ABCB1 (P-glycoprotein)CYP3A4 (Cytochrome P450 3A4)

Beyond the preview

Go deeper on clarithromycin + vinorelbine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clarithromycin + vinorelbine.

Explore the full profile